ArticleFoods (Basel, Switzerland)2026
A Pilot Randomized, Double-Blind, Placebo-Controlled Parallel Group Trial Evaluating the Effect of 8 Week-Consumption of Guava Jelly Drink in Improving Cognition and Mental Well-Being in Working-Age Adults.
Article in Foods (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Given the lack of clinical data supporting the effects of a novel guava jelly drink on cognition and mood regulation, we aimed to explore these effects and their possible mechanisms in working-age volunteers. In an 8-week, three-arm double-blind, placebo-controlled trial, healthy males and females aged 20-40 years old (N = 25/arm) were randomly assigned to consume 86 g per day of either a placebo or guava jelly drink containing either a low (36.6%) or high (73.2%) dose of guava juice with mint syrup. N100 and P300 brain waves, working memory, Perceived Stress Scale (PSS), Hospital Anxiety and Depression Scale (HADS), and biomarkers related to oxidative stress, inflammation, neurotransmitters, and gut microbiota were assessed at baseline and after 4 and 8 weeks of consumption. The low-dose group showed improvements in N100 amplitude, P300 latency, and HADS anxiety score, whereas the high-dose group exhibited improved N100 amplitude, working memory, PSS score, and total HADS score. In addition, the high-dose group also exhibited increased GPx activity without a reduction in MDA. Overall, these results suggest that guava jelly drink positively modulates perceived stress, anxiety, selective attention, and working memory. However, the precise underlying mechanism requires further study.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.